Bortezomib treatment produces nocifensive behavior and changes in the expression of TRPV1, CGRP, and substance P in the Rat DRG, spinal cord, and sciatic nerve

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Quartu, M ^a   Carozzi, V A ^b   Dorsey, S G ^c,d   Serra, M P ^a   Poddighe, L ^a   Picci, C ^a   Boi, M ^a   Melis, T ^a   Del Fiacco, M ^a   Meregalli, C ^b   Chiorazzi, A ^b   Renn, C L ^c   Cavaletti, G ^b   Marmiroli, P ^b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY OF MARYLAND SCHOOL OF NURSING   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CALCITONIN GENE RELATED PEPTIDE; SUBSTANCE P; VANILLOID RECEPTOR 1; BORONIC ACID DERIVATIVE; NERVE PROTEIN; PYRAZINE DERIVATIVE; TRPV1 PROTEIN, RAT; VANILLOID RECEPTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SIZE; CONTROLLED STUDY; FEMALE; INNERVATION; NERVE CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PAIN THRESHOLD; PERIPHERAL NEUROPATHY; PROTEIN EXPRESSION; RAT; SCIATIC NERVE; SINGLE DRUG DOSE; SPINAL CORD; SPINAL CORD DORSAL HORN; SPINAL GANGLION; ANIMAL; ANIMAL BEHAVIOR; BIOSYNTHESIS; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; NOCICEPTION; PATHOLOGY; WISTAR RAT;

ANIMALS; BEHAVIOR, ANIMAL; BORONIC ACIDS; CALCITONIN GENE-RELATED PEPTIDE; DISEASE MODELS, ANIMAL; FEMALE; GANGLIA, SPINAL; GENE EXPRESSION REGULATION; NERVE TISSUE PROTEINS; NOCICEPTION; PERIPHERAL NERVOUS SYSTEM DISEASES; PYRAZINES; RATS; RATS, WISTAR; SCIATIC NERVE; SPINAL CORD; SUBSTANCE P; TRPV CATION CHANNELS;

EID: 84901302647     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/180428     Document Type: Article

References (87)

1. Jagannath S., Barlogie B., Berenson J., Siegel D., Irwin D., Richardson P. G., Niesvizky R., Alexanian R., Limentani S. A., Alsina M., Adams J., Kauffman M., Esseltine D.-L., Schenkein D. P., Anderson K. C., A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. British Journal of Haematology 2004 127 2 165 172 2-s2.0-5644250621 10.1111/j.1365-2141.2004. 05188.x (Pubitemid 39371809)
2. Orlowski R. Z., Bortezomib and its role in the management of patients with multiple myeloma. Expert Review of Anticancer Therapy 2004 4 2 171 179 2-s2.0-1842689611 10.1586/14787210.4.2.171 (Pubitemid 38477331)
3. Mahindra A., Laubach J., Raje N., Munshi N., Richardson P. G., Anderson K., Latest advances and current challenges in the treatment of multiple myeloma. Nature Reviews Clinical Oncology 2012 9 3 135 143 2-s2.0-84857913363 10.1038/nrclinonc.2012.15
4. Fu W., Delasalle K., Wang J., Song S., Hou J., Alexanian R., Wang M., Bortezomib-cyclophosphamide-dexamethasone for relapsing multiple myeloma. American Journal of Clinical Oncology 2011 35 562 565 2-s2.0-79959346932 10.1097/COC.0b013e31822043f6
5. Cusack J. C. Jr., Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treatment Reviews 2003 29 supplement 1 21 31 2-s2.0-0038189917 (Pubitemid 36626289)
6. Davies A. M., Chansky K., Lara P. N., Gumerlock P. H., Crowley J., Albain K. S., Vogel S. J., Gandara D. R., Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II southwest oncology group study (S0339). Journal of Thoracic Oncology 2009 4 1 87 92 2-s2.0-61549138750 10.1097/JTO.0b013e3181915052
7. Kim G. P., Mahoney M. R., Szydlo D., Mok T. S. K., Marshke R., Holen K., Picus J., Boyer M., Pitot H. C., Rubin J., Philip P. A., Nowak A., Wright J. J., Erlichman C., An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. Investigational New Drugs 2012 30 1 387 394 2-s2.0-84856554756 10.1007/s10637-010-9532-1
8. Montagut C., Rovira A., Albanell J., The proteasome: a novel target for anticancer therapy. Clinical and Translational Oncology 2006 8 5 313 317 2-s2.0-33747517230 10.1007/s12094-006-0176-8
9. Nandi D., Tahiliani P., Kumar A., Chandu D., The ubiquitin-proteasome system. Journal of Biosciences 2006 31 1 137 155 2-s2.0-33645669213 10.1007/BF02705243
10. Eldridge A. G., O'Brien T., Therapeutic strategies within the ubiquitin proteasome system. Cell Death and Differentiation 2010 17 1 4 13 2-s2.0-77449103325 10.1038/cdd.2009.82
11. King R. W., Deshaies R. J., Peters J.-M., Kirschner M. W., How proteolysis drives the cell cycle. Science 1996 274 5293 1652 1659 2-s2.0-0029807944 10.1126/science.274.5293.1652 (Pubitemid 26414887)
12. Chen D., Frezza M., Schmitt S., Kanwar J., Dou Q. P., Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Current Cancer Drug Targets 2011 11 3 239 253 2-s2.0-79951702955 10.2174/156800911794519752
13. Read M. A., Neish A. S., Luscinskas F. W., Palombella V. J., Maniatis T., Collins T., The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity 1995 2 5 493 506 2-s2.0-0029010658
14. Voorhees P. M., Dees E. C., O'Neil B., Orlowski R. Z., The proteasome as a target for cancer therapy. Clinical Cancer Research 2003 9 17 6316 6325 2-s2.0-0346333293 (Pubitemid 38031815)
15. Jackson G., Einsele H., Moreau P., San Miguel J., Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies. Cancer Treatment Reviews 2005 31 8 591 602 2-s2.0-27944431658 10.1016/j.ctrv.2005.10. 001 (Pubitemid 41662886)
16. Ludwig H., Khayat D., Giaccone G., Facon T., Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 2005 104 9 1794 1807 2-s2.0-27244460815 10.1002/cncr.21414 (Pubitemid 41513161)
17. Cata J. P., Weng H.-R., Burton A. W., Villareal H., Giralt S., Dougherty P. M., Quantitative sensory findings in patients with bortezomib-induced pain. Journal of Pain 2007 8 4 296 306 2-s2.0-34047253561 10.1016/j.jpain.2006.09.014 (Pubitemid 46551871)
18. Cavaletti G., Jakubowiak A. J., Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leukemia and Lymphoma 2010 51 7 1178 1187 2-s2.0-77954125336 10.3109/10428194.2010.483303
19. Boyette-Davis J. A., Cata J. P., Zhang H., Driver L. C., Wendelschafer-Crabb G., Kennedy W. R., Dougherty P. M., Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients. Journal of Pain 2011 12 9 1017 1024 2-s2.0-80052271730 10.1016/j.jpain.2011.04.008
20. Lanzani F., Mattavelli L., Frigeni B., Rossini F., Cammarota S., Petrò D., Jann S., Cavaletti G., Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity: research report. Journal of the Peripheral Nervous System 2008 13 4 267 274 2-s2.0-58449094350 10.1111/j.1529-8027.2008.00192.x
21. Richardson P., Jagannath S., Colson K., Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma. Clinical Advances in Hematology & Oncology 2006 4 5, supplement 13 1 13 2-s2.0-33846997484
22. Jagannath S., Barlogie B., Berenson J. R., Siegel D. S., Irwin D., Richardson P. G., Niesvizky R., Alexanian R., Limentani S. A., Alsina M., Esseltine D.-L., Anderson K. C., Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. British Journal of Haematology 2008 143 4 537 540 2-s2.0-54849413402 10.1111/j.1365-2141.2008.07359.x
23. Silverman L., Csizmadia V., Cardoza K., Gallacher M., Windman M., Murnane M., Csizmadia E., Bissonnette A., Coleman S., Pierce J., Lane J., Kadambi V. J., Alden C. L., Model for proteasome inhibition associated peripheral neuropathy. Toxicologic Pathology 2006 34 989
24. Poruchynsky M. S., Sackett D. L., Robey R. W., Ward Y., Annunziata C., Fojo T., Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition. Cell Cycle 2008 7 7 940 949 2-s2.0-42449130530 (Pubitemid 351573790)
25. Csizmadia V., Csizmadia E., Silverman L., Simpson C., Raczynski A., O'Brien L., Gallacher M., Cardoza K., Kadambi V. J., Fedyk E. R., Alden C. L., Effect of proteasome inhibitors with different chemical structures on the ubiquitin-proteasome system in vitro. Veterinary Pathology 2010 47 2 358 367 2-s2.0-77954023420 10.1177/0300985809358423
26. Casafont I., Berciano M. T., Lafarga M., Bortezomib induces the formation of nuclear poly(A) RNA granules enriched in Sam68 and PABPN1 in sensory ganglia neurons. Neurotoxicity Research 2010 17 2 167 178 2-s2.0-77449161209 10.1007/s12640-009-9086-1
27. Argyriou A. A., Bruna J., Marmiroli P., Cavaletti G., Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Critical Reviews in Oncology/Hematology 2012 82 1 51 77 2-s2.0-84858799716 10.1016/j.critrevonc.2011.04.012
28. Meregalli C., Canta A., Carozzi V. A., Chiorazzi A., Oggioni N., Gilardini A., Ceresa C., Avezza F., Crippa L., Marmiroli P., Cavaletti G., Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats. European Journal of Pain 2010 14 4 343 350 2-s2.0-77949912801 10.1016/j.ejpain.2009.07.001
29. Meregalli C., Ceresa C., Canta A., Carozzi V. A., Chiorazzi A., Sala B., Oggioni N., Lanza M., Letari O., Ferrari F., Avezza F., Marmiroli P., Caselli G., Cavaletti G., CR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats. Journal of Pain Research 2012 5 151 167
30. Szallasi A., Cortright D. N., Blum C. A., Eid S. R., The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nature Reviews Drug Discovery 2007 6 5 357 372. Erratum in: Nature Reviews Drug Discovery, vol. 6, p. 442, 2007 2-s2.0-34248138496 10.1038/nrd2280 (Pubitemid 46705200)
31. Moran M. M., McAlexander M. A., Bíró T., Szallasi A., Transient receptor potential channels as therapeutic targets. Nature Reviews Drug Discovery 2011 10 8 601 620 2-s2.0-79960997710 10.1038/nrd3456
32. Tominaga M., Calerina M. J., Thermosensation and pain. Journal of Neurobiology 2004 61 1 3 12 2-s2.0-4644324408 10.1002/neu.20079 (Pubitemid 39302620)
33. Pomonis J. D., Harrison J. E., Mark L., Bristol D. R., Valenzano K. J., Walker K., N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl) tetrahydropyrazine-1 (2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. In vivo characterization in rat models of inflammatory and neuropathic pain. Journal of Pharmacology and Experimental Therapeutics 2003 306 1 387 393 2-s2.0-0038128285 10.1124/jpet.102.046268 (Pubitemid 36734396)
34. Cui M., Honore P., Zhong C., Gauvin D., Mikusa J., Hernandez G., Chandran P., Gomtsyan A., Brown B., Bayburt E. K., Marsh K., Bianchi B., McDonald H., Niforatos W., Neelands T. R., Moreland R. B., Decker M. W., Lee C.-H., Sullivan J. P., Faltynek C. R., TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists. Journal of Neuroscience 2006 26 37 9385 9393 2-s2.0-33748680717 10.1523/JNEUROSCI.1246-06.2006 (Pubitemid 44396851)
35. Culshaw A. J., Bevan S., Christiansen M., Copp P., Davis A., Davis C., Dyson A., Dziadulewicz E. K., Edwards L., Eggelte H., Fox A., Gentry C., Groarke A., Hallett A., Hart T. W., Hughes G. A., Knights S., Kotsonis P., Lee W., Lyothier I., McBryde A., McIntyre P., Paloumbis G., Panesar M., Patel S., Seiler M.-P., Yaqoob M., Zimmermann K., Identification and biological characterization of 6-aryl-7-isopropylquinazolinones as novel TRPV1 antagonists that are effective in models of chronic pain. Journal of Medicinal Chemistry 2006 49 2 471 474 2-s2.0-31544449199 10.1021/jm051058x (Pubitemid 43157481)
36. McGaraughty S., Chu K. L., Brown B. S., Zhu C. Z., Zhong C., Joshi S. K., Honore P., Faltynek C. R., Jarvis M. F., Contributions of central and peripheral TRPV1 receptors to mechanically evoked and spontaneous firing of spinal neurons in inflamed rats. Journal of Neurophysiology 2008 100 6 3158 3166 2-s2.0-57449098039 10.1152/jn.90768.2008
37. Holzer P., The pharmacological challenge to tame the transient receptor potential vanilloid-1 (TRPV1) nocisensor. British Journal of Pharmacology 2008 155 8 1145 1162 2-s2.0-57549118558 10.1038/bjp.2008.351
38. Priestley J. V., Michael G. J., Averill S., Liu M., Willmott N., Regulation of nociceptive neurons by nerve growth factor and glial cell line derived neurotrophic factor. Canadian Journal of Physiology and Pharmacology 2002 80 5 495 505 2-s2.0-0036099051 10.1139/y02-034 (Pubitemid 34539428)
39. Szallasi A., Blumberg P. M., Vanilloid (Capsaicin) receptors and mechanisms. Pharmacological Reviews 1999 51 2 159 211 2-s2.0-0032970173 (Pubitemid 29269981)
40. Cavaletti G., Gilardini A., Canta A., Rigamonti L., Rodriguez-Menendez V., Ceresa C., Marmiroli P., Bossi M., Oggioni N., D'Incalci M., De Coster R., Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Experimental Neurology 2007 204 1 317 325 2-s2.0-33847293709 10.1016/j.expneurol.2006.11.010 (Pubitemid 46330280)
41. Cavaletti G., Tredici G., Marmiroli P., Petruccioli M. G., Barajon I., Fabbrica D., Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathologica 1992 84 4 364 371 2-s2.0-0026700476
42. Cavaletti G., Cavalletti E., Montaguti P., Oggioni N., De Negri O., Tredici G., Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. NeuroToxicology 1997 18 1 137 146 2-s2.0-0030986866 (Pubitemid 27280124)
43. Cavaletti G., Fabbrica D., Minoia C., Frattola L., Tredici G., Carboplatin toxic effects on the peripheral nervous system of the rat. Annals of Oncology 1998 9 4 443 447 2-s2.0-0031800167 10.1023/A:1008231925889 (Pubitemid 28273039)
44. Cavaletti G., Cavalletti E., Oggioni N., Sottani C., Minoia C., D'Incalci M., Zucchetti M., Marmiroli P., Tredici G., Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration. NeuroToxicology 2000 21 3 389 394 2-s2.0-0033946212 (Pubitemid 30436437)
45. Cavaletti G., Oggioni N., Sala F., Pezzoni G., Cavalletti E., Marmiroli P., Petruccioli M. G., Frattola L., Tredici G., Effect on the peripheral nervous system of systemically administered dimethylsulfoxide in the rat: a neurophysiological and pathological study. Toxicology Letters 2000 118 1-2 103 107 2-s2.0-0034694779 10.1016/S0378-4274(00)00269-1 (Pubitemid 32008400)
46. Cavaletti G., Tredici G., Petruccioli M. G., Dondè E., Tredici P., Marmiroli P., Minoia C., Ronchi A., Bayssas M., Griffon Etienne G., Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. European Journal of Cancer 2001 37 18 2457 2463 2-s2.0-0035196664 10.1016/S0959-8049(01)00300-8 (Pubitemid 33097486)
47. Tredici G., Braga M., Nicolini G., Miloso M., Marmiroli P., Schenone A., Nobbio L., Frattola L., Cavaletti G., Effect of recombinant human nerve growth factor on cisplatin neurotoxicity in rats. Experimental Neurology 1999 159 2 551 558 2-s2.0-0032874159 10.1006/exnr.1999.7174 (Pubitemid 29485242)
48. Pisano C., Pratesi G., Laccabue D., Zunino F., Giudice P. L., Bellucci A., Pacifici L., Camerini B., Vesci L., Castorina M., Cicuzza S., Tredici G., Marmiroli P., Nicolini G., Galbiati S., Calvani M., Carminati P., Cavaletti G., Paclitaxel and cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clinical Cancer Research 2003 9 15 5756 5767 2-s2.0-0345060438 (Pubitemid 37499500)
49. Rosenbaum T., Awaya M., Gordon S. E., Subunit modification and association in VR1 ion channels. BMC Neuroscience 2002 3, article 4 2-s2.0-0037155988 10.1186/1471-2202-3-4 (Pubitemid 38729143)
50. Reagan-Shaw S., Nihal M., Ahmad N., Dose translation from animal to human studies revisited. The FASEB Journal 2008 22 3 659 661 2-s2.0-40449086665 10.1096/fj.07-9574LSF (Pubitemid 351348146)
51. Meregalli C., Chiorazzi A., Carozzi V. A., Canta A., Sala B., Oggioni N., Ceresa C., Foudah D., La Russa F., Miloso M., Nicolini G., Marmiroli P., Bennett D. L., Cavaletti G., Evaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomib-induced peripheral neuropathy. Cell Cycle 2013 13 4 10.4161/cc.27476
52. Shimizu T., Shibata M., Toriumi H., Iwashita T., Funakubo M., Sato H., Kuroi T., Ebine T., Koizumi K., Suzuki N., Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-A. Neurobiology of Disease 2012 48 367 378 10.1016/j.nbd.2012.07.010
53. Shin Y. K., Jang S. Y., Lee H. K., Jung J., Suh D. J., Seo S.-Y., Park H. T., Pathological adaptive responses of schwann cells to endoplasmic reticulum stress in bortezomib-induced peripheral neuropathy. GLIA 2010 58 16 1961 1976 2-s2.0-78649421033 10.1002/glia.21065
54. Bruna J., Udina E., Alé A., Vilches J. J., Vynckier A., Monbaliu J., Silverman L., Navarro X., Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice. Experimental Neurology 2010 223 2 599 608 2-s2.0-77952544961 10.1016/j.expneurol.2010.02.006
55. Yang F., Jove V., Chang S., Hedvat M., Liu L., Buettner R., Tian Y., Scuto A., Wen W., Yip M. L. R., Van Meter T. E., Yen Y., Jove R., Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF B signaling, and synergizes with an ERK inhibitor. Cancer Biology and Therapy 2012 13 6 349 357 2-s2.0-84860255301 10.4161/cbt.13.6.19239
56. Mühlen S., Ruchaud-Sparagano M.-H., Kenny B., Proteasome-independent degradation of canonical NF B complex components by the NleC protein of pathogenic Escherichia coli. Journal of Biological Chemistry 2011 286 7 5100 5107 2-s2.0-79953046297 10.1074/jbc.M110.172254
57. Pearson J. S., Riedmaier P., Marchès O., Frankel G., Hartland E. L., A type III effector protease NleC from enteropathogenic Escherichia coli targets NF- B for degradation. Molecular Microbiology 2011 80 1 219 230 2-s2.0-79953057642 10.1111/j.1365-2958.2011.07568.x
58. Winter J., Malmberg A. B., Bley K. R., TRPV1 distribution and regulation. Turning Up the Heat on Pain: TRPV1 Receptors in Pain and Inflammation 2005 Basel, Switzerland Birkhauser 39 51
59. Hideshima T., Ikeda H., Chauhan D., Okawa Y., Raje N., Podar K., Mitsiades C., Munshi N. C., Richardson P. G., Carrasco R. D., Anderson K. C., Bortezomib induces canonical nuclear factor- B activation in multiple myeloma cells. Blood 2009 114 5 1046 1052 2-s2.0-70349243697 10.1182/blood-2009-01- 199604
60. Trevisan G., Materazzi S., Fusi C., Altomare A., Aldini G., Lodovici M., Patacchini R., Geppetti P., Nassini R., Novel therapeutic strategy to prevent chemotherapy-induced persistent sensory neuropathy by TRPA1 blockade. Cancer Research 2013 73 3120 3131 10.1158/0008-5472.CAN-12-4370
61. Schwartz R., Davidson T., Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology (Williston Park, N.Y.) 2004 18 14, supplement 11 14 21 2-s2.0-17644379385
62. Yu L., Yang F., Luo H., Liu F.-Y., Han J.-S., Xing G.-G., Wan Y., The role of TRPV1 in different subtypes of dorsal root ganglion neurons in rat chronic inflammatory nociception induced by complete Freund's adjuvant. Molecular Pain 2008 4, article 61 2-s2.0-58749096723 10.1186/1744-8069-4-61
63. Argyriou A. A., Iconomou G., Kalofonos H. P., Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008 112 5 1593 1599. Erratum in: Blood, vol. 113. p. 4478, 2009 2-s2.0-52649114697 10.1182/blood-2008-04-149385
64. Adams J., Kauffman M., Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Investigation 2004 22 2 304 311 2-s2.0-2642551603 10.1081/CNV-120030218 (Pubitemid 38725184)
65. Mezey É., Tóth Z. E., Cortright D. N., Arzubi M. K., Krause J. E., Elde R., Guo A., Blumberg P. M., Szallasi A., Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proceedings of the National Academy of Sciences of the United States of America 2000 97 7 3655 3660 2-s2.0-0034724402 (Pubitemid 30183358)
66. Honore P., Wismer C. T., Mikusa J., Zhu C. Z., Zhong C., Gauvin D. M., Gomtsyan A., El Kouhen R., Lee C.-H., Marsh K., Sullivan J. P., Faltynek C. R., Jarvis M. F., A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats. Journal of Pharmacology and Experimental Therapeutics 2005 314 1 410 421 2-s2.0-23044496253 10.1124/jpet.105.083915 (Pubitemid 41058279)
67. Sanchez J. F., Krause J. E., Cortright D. N., The distribution and regulation of vanilloid receptor VR1 and VR1 5′ splice variant RNA expression in rat. Neuroscience 2001 107 3 373 381 2-s2.0-0035940785 10.1016/S0306-4522(01)00373-6 (Pubitemid 33079114)
68. Kim Y. H., Back S. K., Davies A. J., Jeong H., Jo H. J., Chung G., Na S., Bae Y. C., Kim S. J., Kim J. S., Jung S. J., Oh S. B., TRPV1 in GABAergic interneurons mediates neuropathic mechanical allodynia and disinhibition of the nociceptive circuitry in the spinal cord. Neuron 2012 74 640 647 10.1016/j.neuron.2012.02.039
69. Doly S., Fischer J., Salio C., Conrath M., The vanilloid receptor-1 is expressed in rat spinal dorsal horn astrocytes. Neuroscience Letters 2004 357 2 123 126 2-s2.0-1242292301 10.1016/j.neulet.2003.12.051 (Pubitemid 38230946)
70. Chen Y., Willcockson H. H., Valtschanoff J. G., Influence of the vanilloid receptor TRPV1 on the activation of spinal cord glia in mouse models of pain. Experimental Neurology 2009 220 2 383 390 2-s2.0-71549147547 10.1016/j.expneurol.2009.09.030
71. Tohda C., Sasaki M., Konemur T., Sasamura T., Itoh M., Kuraishi Y., Axonal transport of VR1 capsaicin receptor mRNA in primary afferents and its participation in inflammation-induced increase in capsaicin sensitivity. Journal of Neurochemistry 2001 76 6 1628 1635 2-s2.0-0035109136 10.1046/j.1471-4159. 2001.00193.x (Pubitemid 32221102)
72. Barajon I., Bersani M., Quartu M., Del Fiacco M., Cavaletti G., Holst J. J., Tredici G., Neuropeptides and morphological changes in cisplatin-induced dorsal root ganglion neuronopathy. Experimental Neurology 1996 138 1 93 104 2-s2.0-0029871951 10.1006/exnr.1996.0050 (Pubitemid 26107992)
73. Verdú E., Vilches J. J., Rodríguez F. J., Ceballos D., Valero A., Navarro X., Physiological and immunohistochemical characterization of cisplatin-induced neuropathy in mice. Muscle & Nerve 1999 22 329 340 10.1002/(SICI)1097-4598(199903)22:3<329::AID-MUS5>3.0.CO;2-8 (Pubitemid 29116186)
74. Horvath P., Szilvassy J., Nemeth J., Peitl B., Szilasi M., Szilvassy Z., Decreased sensory neuropeptide release in isolated bronchi of rats with cisplatin-induced neuropathy. European Journal of Pharmacology 2005 507 1-3 247 252 2-s2.0-12344338368 10.1016/j.ejphar.2004.11.053 (Pubitemid 40126861)
75. Alessandri-Haber N., Dina O. A., Joseph E. K., Reichling D. B., Levine J. D., Interaction of transient receptor potential vanilloid 4, integrin, and Src tyrosine kinase in mechanical hyperalgesia. Journal of Neuroscience 2008 28 5 1046 1057 2-s2.0-38749148787 10.1523/JNEUROSCI.4497-07.2008 (Pubitemid 351186354)
76. Ta L. E., Bieber A. J., Carlton S. M., Loprinzi C. L., Low P. A., Windebank A. J., Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice. Molecular Pain 2010 6, article 15 2-s2.0-77951173732 10.1186/1744-8069-6-15
77. Zhao M., Isami K., Nakamura S., Shirakawa H., Nakagawa T., Kaneko S., Acute cold hypersensitivity characteristically induced by oxaliplatin is caused by the enhanced responsiveness of TRPA1 in mice. Molecular Pain 2012 8 55 10.1186/1744-8069-8-55
78. Hara T., Chiba T., Abe K., Makabe A., Ikeno S., Kawakami K., Utsunomiya I., Hama T., Taguchi K., Effect of paclitaxel on transient receptor potential vanilloid 1 in rat dorsal root ganglion. Pain 2013 154 882 889 10.1016/j.pain.2013.02.023
79. Hudson L. J., Bevan S., Wotherspoon G., Gentry C., Fox A., Winter J., VR1 protein expression increases in undamaged DRG neurons after partial nerve injury. European Journal of Neuroscience 2001 13 11 2105 2114 2-s2.0-0034954583 10.1046/j.0953-816X.2001.01591.x (Pubitemid 32578796)
80. Kim H. Y., Park C.-K., Cho I.-H., Jung S. J., Kim J. S., Oh S. B., Differential Changes in TRPV1 expression after trigeminal sensory nerve injury. Journal of Pain 2008 9 3 280 288 2-s2.0-39649086277 10.1016/j.jpain.2007.11.013
81. Zheng L.-F., Wang R., Xu Y.-Z., Yi X.-N., Zhang J.-W., Zeng Z.-C., Calcitonin gene-related peptide dynamics in rat dorsal root ganglia and spinal cord following different sciatic nerve injuries. Brain Research 2008 1187 1 20 32 2-s2.0-36549078060 10.1016/j.brainres.2007.10.044 (Pubitemid 350191806)
82. Ménard D. P., Van Rossum D., Kar S., St. Pierre S., Sutak M., Jhamandas K., Quirion R., A calcitonin gene-related peptide receptor antagonist prevents the development of tolerance to spinal morphine analgesia. Journal of Neuroscience 1996 16 7 2342 2351 2-s2.0-0029945840 (Pubitemid 26154344)
83. Ma W., Bisby M. A., Calcitonin gene-related peptide, substance P and protein gene product 9.5 immunoreactive axonal fibers in the rat footpad skin following partial sciatic nerve injuries. Brain Cell Biology 2000 29 4 249 262 2-s2.0-54249093002
84. Chao T., Pham K., Steward O., Gupta R., Chronic nerve compression injury induces a phenotypic switch of neurons within the dorsal root ganglia. Journal of Comparative Neurology 2008 506 2 180 193 2-s2.0-38049085622 10.1002/cne.21537
85. Li X.-Q., Verge V. M. K., Johnston J. M., Zochodne D. W., CGRP peptide and regenerating sensory axons. Journal of Neuropathology and Experimental Neurology 2004 63 10 1092 1103 2-s2.0-5644264789 (Pubitemid 39372593)
86. Caviedes-Bucheli J., Moreno J. O., Ardila-Pinto J., Del Toro-Carreño H. R., Saltarín-Quintero H., Sierra-Tapias C. L., MacIas-Gomez F., Ulate E., Lombana-Sanchez N., Munoz H. R., The effect of orthodontic forces on calcitonin gene-related peptide expression in human dental pulp. Journal of Endodontics 2011 37 7 934 937 2-s2.0-79959376375 10.1016/j.joen.2011.03.035
87. Guo A., Immunocytochemical localization of the vanilloid receptor 1 (VR1): relationship to neliropeptides, the P2X3 purinoceptor and IB4 binding sites. European Journal of Neuroscience 1999 11 3 946 958 2-s2.0-0032967640 (Pubitemid 29106055)